Symbols / PMN Stock $11.24 +3.31% ProMIS Neurosciences, Inc.

Healthcare • Biotechnology • Canada • NCM
PMN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Neil K. Warma M.B.A.
Exch · Country NCM · Canada
Market Cap 100.80M
Enterprise Value 94.65M
Income -39.72M
Sales —
FCF (ttm) -13.32M
Book/sh -0.58
Cash/sh 0.69
Employees 10
Insider 10d —
IPO Jan 10, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -18.43
PEG —
P/S —
P/B -19.21
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 0.59
Current Ratio 0.88
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -22.61
EPS next Y -0.61
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-25
Earnings (prior) 2026-03-25
ROA -176.49%
ROE -5.22%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 8.97M
Shs Float 4.60M
Insider Own 20.43%
Instit Own 32.77%
Short Float 1.55%
Short Ratio 3.52
Short Interest 138.08K
52W High 39.75
vs 52W High -71.72%
52W Low 6.27
vs 52W Low 79.27%
Beta -0.15
Impl. Vol. —
Rel Volume 0.17
Avg Volume 179.53K
Volume 31.37K
Target (mean) $34.65
Tgt Median $35.19
Tgt Low $18.24
Tgt High $49.99
# Analysts 4
Recom None
Prev Close $10.88
Price $11.24
Change 3.31%
About

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$34.65
Mean price target
2. Current target
$11.24
Latest analyst target
3. DCF / Fair value
$-26.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.24
Low
$18.24
High
$49.99
Mean
$34.65

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-06 main Guggenheim Buy → Buy $35
2025-12-01 main HC Wainwright & Co. Buy → Buy $18
2025-11-21 reit HC Wainwright & Co. Buy → Buy $4
2025-11-18 main Guggenheim Buy → Buy $5
2025-07-14 init HC Wainwright & Co. — → Buy $4
2025-05-12 init Maxim Group — → Buy $3
2025-04-01 reit Guggenheim Buy → Buy $6
2025-02-26 reit Guggenheim Buy → Buy —
News
RSS: Latest PMN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 WILLIAMS EUGENE WARREN Director — 2,000 $24.40 $48,800
2026-03-04 WILLIAMS EUGENE WARREN Director — 4,000 $21.89 $92,420
2026-02-19 KAPLAN JOHANNE Officer — 1,629 $15.35 $25,005
2026-02-03 WARMA NEIL K Chief Executive Officer — 6,183 $15.90 $98,310
2026-02-03 ABG MANAGEMENT, LTD. Beneficial Owner of more than 10% of a Class of Security — 700,741 $15.90 $11,141,782
2026-02-03 KIRWIN PATRICK D Director — 3,050 $15.90 $48,495
2026-02-03 MILBURY MAX A. Officer — 6,595 $15.90 $104,860
2026-02-03 KAPLAN JOHANNE Officer — 2,060 $15.90 $32,754
2026-02-03 CASHMAN NEIL Officer and Director — 4,122 $15.90 $65,540
2025-10-03 MILBURY MAX A. Officer — 30,392 $0.49 $14,929
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
40.17
+138.70%
16.83
+17.98%
14.26
-39.00%
23.38
Research And Development
33.38
+213.78%
10.64
+34.95%
7.88
-51.00%
16.09
Selling General And Administration
6.79
+9.67%
6.19
-2.98%
6.38
-12.52%
7.29
General And Administrative Expense
6.79
+9.67%
6.19
-2.98%
6.38
-12.52%
7.29
Other Gand A
6.79
+9.67%
6.19
-2.98%
6.38
-12.52%
7.29
Total Expenses
40.17
+138.70%
16.83
+17.98%
14.26
-39.00%
23.38
Operating Income
-40.17
-138.70%
-16.83
-17.98%
-14.26
+39.00%
-23.38
Total Operating Income As Reported
-40.17
-138.70%
-16.83
-17.98%
-14.26
+39.00%
-23.38
EBITDA
-39.72
-1490.90%
2.86
+121.98%
-12.99
+26.90%
-17.77
Normalized EBITDA
-39.72
-101.38%
-19.73
-42.36%
-13.86
+40.41%
-23.25
Reconciled Depreciation
—
0.00
-100.00%
0.02
+88.65%
0.01
EBIT
-39.72
-1490.90%
2.86
+121.95%
-13.01
+26.82%
-17.78
Total Unusual Items
0.01
-99.98%
22.58
+2505.34%
0.87
-84.20%
5.48
Total Unusual Items Excluding Goodwill
0.01
-99.98%
22.58
+2505.34%
0.87
-84.20%
5.48
Special Income Charges
—
—
0.00
-100.00%
1.31
Other Special Charges
—
—
—
-1.31
Net Income
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Pretax Income
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Net Non Operating Interest Income Expense
0.00
+100.00%
-0.08
+61.88%
-0.20
+28.60%
-0.28
Interest Expense Non Operating
0.00
-100.00%
0.08
-61.88%
0.20
-28.60%
0.28
Net Interest Income
0.00
+100.00%
-0.08
+61.88%
-0.20
+28.60%
-0.28
Interest Expense
0.00
-100.00%
0.08
-61.88%
0.20
-28.60%
0.28
Interest Income Non Operating
—
—
—
—
Interest Income
—
—
—
—
Other Income Expense
0.45
-97.72%
19.68
+1472.59%
1.25
-77.65%
5.60
Other Non Operating Income Expenses
0.44
+115.27%
-2.90
-853.01%
0.38
+233.18%
0.12
Gain On Sale Of Security
0.01
-99.98%
22.58
+2505.34%
0.87
-79.25%
4.18
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
3.39
0.00
0.00
Net Income Including Noncontrolling Interests
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Net Income From Continuing Operation Net Minority Interest
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Net Income From Continuing And Discontinued Operation
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Net Income Continuous Operations
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Normalized Income
-39.72
-142.00%
-16.42
-16.59%
-14.08
+40.21%
-23.55
Net Income Common Stockholders
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Diluted EPS
-22.61
-959.70%
2.63
+109.83%
-26.75
+55.60%
-60.25
Basic EPS
-22.61
-943.66%
2.68
+110.02%
-26.75
+55.60%
-60.25
Basic Average Shares
1.76
+69.45%
1.04
+110.86%
0.49
+63.85%
0.30
Diluted Average Shares
1.76
+65.98%
1.06
+115.26%
0.49
+63.85%
0.30
Diluted NI Availto Com Stockholders
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Gain On Sale Of PPE
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
13.62
Current Assets
13.62
Cash Cash Equivalents And Short Term Investments
12.63
Cash And Cash Equivalents
12.60
Cash Financial
12.60
Other Short Term Investments
0.03
Receivables
0.08
Other Receivables
—
Taxes Receivable
0.02
Accrued Interest Receivable
0.08
Prepaid Assets
0.68
Current Deferred Assets
0.20
Other Current Assets
0.03
Total Non Current Assets
0.00
Net PPE
0.00
Gross PPE
—
Accumulated Depreciation
—
Machinery Furniture Equipment
—
Other Properties
—
Goodwill And Other Intangible Assets
0.00
Investments And Advances
—
Long Term Equity Investment
—
Total Liabilities Net Minority Interest
9.87
Current Liabilities
9.35
Payables And Accrued Expenses
8.83
Payables
7.84
Accounts Payable
7.84
Current Accrued Expenses
0.99
Employee Benefits
0.42
Pensionand Other Post Retirement Benefit Plans Current
0.52
Current Deferred Liabilities
—
Total Non Current Liabilities Net Minority Interest
0.52
Long Term Debt And Capital Lease Obligation
—
Long Term Debt
—
Stockholders Equity
3.75
Common Stock Equity
3.75
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.76
Ordinary Shares Number
0.76
Treasury Shares Number
0.00
Additional Paid In Capital
97.59
Retained Earnings
-93.47
Gains Losses Not Affecting Retained Earnings
-0.37
Other Equity Adjustments
-0.37
Total Equity Gross Minority Interest
3.75
Total Capitalization
3.75
Working Capital
4.27
Invested Capital
3.75
Total Debt
—
Net Tangible Assets
3.75
Tangible Book Value
3.75
Derivative Product Liabilities
0.09
Interest Payable
—
Investmentsin Joint Venturesat Cost
—
Other Equity Interest
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.12
-3.45%
-27.18
-150.67%
-10.84
+36.34%
-17.03
Cash Flow From Continuing Operating Activities
-28.12
-3.45%
-27.18
-150.67%
-10.84
+36.34%
-17.03
Net Income From Continuing Operations
-39.72
-1529.33%
2.78
+121.03%
-13.21
+26.85%
-18.06
Depreciation Amortization Depletion
—
0.00
-100.00%
0.02
+88.65%
0.01
Depreciation
—
0.00
-100.00%
0.00
-94.78%
0.01
Amortization Cash Flow
—
0.00
-100.00%
0.02
+310.84%
0.01
Depreciation And Amortization
—
0.00
-100.00%
0.02
+88.65%
0.01
Amortization Of Intangibles
—
0.00
-100.00%
0.02
+310.84%
0.01
Other Non Cash Items
—
3.52
—
0.24
Stock Based Compensation
0.86
+3.85%
0.83
+204.12%
0.27
-44.31%
0.49
Operating Gains Losses
-0.01
+99.98%
-22.58
-2499.89%
-0.87
+83.02%
-5.11
Gain Loss On Investment Securities
-0.01
+99.98%
-22.58
-2505.34%
-0.87
+78.93%
-4.11
Net Foreign Currency Exchange Gain Loss
—
0.00
+100.00%
-0.00
-100.59%
0.31
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
10.75
+191.63%
-11.73
-498.34%
2.94
-45.50%
5.40
Change In Receivables
—
—
—
—
Change In Prepaid Assets
2.56
+155.56%
-4.60
-2354.93%
-0.19
+41.23%
-0.32
Change In Payables And Accrued Expense
8.19
+214.89%
-7.13
-327.69%
3.13
-45.26%
5.72
Change In Accrued Expense
7.39
+820.33%
-1.03
+44.00%
-1.83
-160.13%
3.05
Change In Payable
0.81
+113.20%
-6.11
-223.02%
4.96
+85.49%
2.68
Change In Account Payable
0.81
+113.20%
-6.11
-223.02%
4.96
+85.49%
2.68
Change In Other Working Capital
—
—
—
—
Investing Cash Flow
-0.00
-1.30%
-0.00
+48.63%
-0.00
+31.90%
-0.00
Cash Flow From Continuing Investing Activities
-0.00
-1.30%
-0.00
+48.63%
-0.00
+31.90%
-0.00
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.00
Purchase Of PPE
—
—
0.00
+100.00%
-0.00
Sale Of PPE
—
—
—
0.00
Capital Expenditure
—
—
—
-0.00
Net Investment Purchase And Sale
-0.00
-1.30%
-0.00
+48.63%
-0.00
0.00
Purchase Of Investment
-0.03
-2.12%
-0.03
-2.14%
-0.03
-4.35%
-0.03
Sale Of Investment
0.03
+2.14%
0.03
+4.35%
0.03
+0.00%
0.03
Net Business Purchase And Sale
—
—
—
—
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
20.94
-24.86%
27.88
+57.06%
17.75
+173.28%
6.49
Cash Flow From Continuing Financing Activities
20.94
-24.86%
27.88
+57.06%
17.75
+173.28%
6.49
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
20.24
-27.30%
27.85
+56.93%
17.75
+256.74%
4.97
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
0.70
+2399.14%
0.03
+678.83%
0.00
-99.76%
1.52
Changes In Cash
-7.17
-1135.27%
0.69
-89.96%
6.90
+165.49%
-10.54
Effect Of Exchange Rate Changes
—
0.00
+100.00%
-0.18
+65.57%
-0.53
Beginning Cash Position
13.29
+5.50%
12.60
+114.41%
5.88
-65.32%
16.94
End Cash Position
6.12
-53.98%
13.29
+5.50%
12.60
+114.41%
5.88
Free Cash Flow
-28.12
-3.45%
-27.18
-150.67%
-10.84
+36.35%
-17.04
Interest Paid Supplemental Data
0.00
-100.00%
0.08
-61.88%
0.20
+131.30%
0.09
Common Stock Issuance
20.24
-27.30%
27.85
+56.93%
17.75
+256.74%
4.97
Issuance Of Capital Stock
20.24
-27.30%
27.85
+56.93%
17.75
+256.74%
4.97
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category